JMP Securities Reiterates Market Outperform on Madrigal Pharmaceuticals, Maintains $347 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben has reiterated a 'Market Outperform' rating on Madrigal Pharmaceuticals (MDGL) and maintained a price target of $347.
February 16, 2024 | 7:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities analyst Jonathan Wolleben has reiterated a 'Market Outperform' rating on Madrigal Pharmaceuticals with a maintained price target of $347.
The reiteration of a 'Market Outperform' rating and the maintenance of a high price target ($347) by a reputable analyst like Jonathan Wolleben from JMP Securities could instill confidence among investors and potentially lead to a positive short-term price movement for MDGL. The analyst's endorsement serves as a strong signal of the company's robust fundamentals and growth prospects.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100